Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1923

Sort by

Sort Order Select

Journal Articles

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi

Blood Adv (2025) 9 (12): 2927–2934.

https://doi.org/10.1182/bloodadvances.2024014790

Published: 2025

Includes: Supplemental data

Journal Articles

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Eleftheria Kampouri, Patrick Flaherty, Hu Xie, Mandeep K. Sekhon, Clementine Chalal, Terry L. Stevens-Ayers, Damian J. Green, Jordan Gauthier, Mazyar Shadman, Ailyn C. Pérez-Osorio, Keith R. Jerome, Wendy M. Leisenring, Michael J. Boeckh, Joshua A. Hill

Blood Adv (2025) 9 (12): 2997–3001.

https://doi.org/10.1182/bloodadvances.2024015164

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma

Joshua N. Gustine, Andrew R. Branagan, Diana D. Cirstea, Farah Rexha, Ryan Han, Andrew J. Yee, Marcela V. Maus, Matthew J. Frigault, Noopur S. Raje

Blood Adv (2025) 9 (12): 3026–3030.

https://doi.org/10.1182/bloodadvances.2025015981

Published: 2025

Includes: Supplemental data

Journal Articles

Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies

Steven Pipe, Allen Poma, Anita Rajasekhar, Tamara Everington, Serap Sankoh, Jack Allen, Jason Cataldo, Eric Crombez

Blood Adv (2025) 9 (12): 2980–2987.

https://doi.org/10.1182/bloodadvances.2024015184

Published: 2025

Journal Articles

A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma

Blood Adv bloodadvances.2025016483.

https://doi.org/10.1182/bloodadvances.2025016483

Published: 2025

Includes: Supplemental data

Journal Articles

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

Konstantinos Lontos, Rima M. Saliba, Rashmi Kanagal-Shamanna, Gonca Özcan, Jeremy Ramdial, George Chen, Tapan Kadia, Nicholas James Short, Naval G. Daver, Hagop Kantarjian, David Marin, Partow Kebriaei, Uday Popat, Richard Champlin, Elizabeth Shpall, Betül Oran

Blood Adv (2025) 9 (11): 2845–2854.

https://doi.org/10.1182/bloodadvances.2024014499

Published: 2025

Journal Articles

Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations

Stephanie Sendker, Markus Schneider, Evangelia Antoniou, Daniel Neumann, Naghmeh Niktoreh, Uta Dirksen, Nils von Neuhoff, Ursula Creutzig, Dirk Reinhardt, Katharina Waack

Blood Adv (2025) 9 (11): 2831–2841.

https://doi.org/10.1182/bloodadvances.2024014728

Published: 2025

Includes: Supplemental data

Journal Articles

A cure for the kiss of death?

Jacob S. Appelbaum, Mary-Elizabeth Percival, Bart L. Scott

Blood Adv (2025) 9 (11): 2855–2856.

https://doi.org/10.1182/bloodadvances.2025015850

Published: 2025

Journal Articles

On the road to improved therapies for therapy-related AML

Alexandra McLean Stevens, Todd M. Cooper

Blood Adv (2025) 9 (11): 2842–2844.

https://doi.org/10.1182/bloodadvances.2025015987

Published: 2025

Journal Articles

Prebiotic fibre enteral supplementation post allogeneic transplantation; feasibility and impact on the microbiome

Sarah Andersen, PhD, Adv APD, Glen A Kennedy, Merrilyn Banks, Bernadine Mary Flanagan, BSc (Hons) PhD, Andrea S Henden

Blood Adv bloodadvances.2024015703.

https://doi.org/10.1182/bloodadvances.2024015703

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Concomitant Azoles on Ruxolitinib Treatment in Patients With GVHD: Post Hoc Analyses of REACH2 and REACH3

Zahra Mahmoudjafari, Emily Kintsch, Zhenyi Xue, Valkal Bhatt, John Galvin, Franco Locatelli, Robert Zeiser

Blood Adv bloodadvances.2025016212.

https://doi.org/10.1182/bloodadvances.2025016212

Published: 2025

Journal Articles

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

Blood Adv bloodadvances.2025016513.

https://doi.org/10.1182/bloodadvances.2025016513

Published: 2025

Journal Articles

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Blood Adv (2025) 9 (11): 2763–2772.

https://doi.org/10.1182/bloodadvances.2024014846

Published: 2025

Includes: Supplemental data

Journal Articles

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA

Michael D. Tarantino, Kailash Mosalpuria, Scott Kolodny, Jessica Zhang, Michael Vredenburg, Brian D. Jamieson

Blood Adv (2025) 9 (11): 2733–2743.

https://doi.org/10.1182/bloodadvances.2024015635

Published: 2025

Includes: Supplemental data

Journal Articles

Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR

Blood Adv bloodadvances.2025016141.

https://doi.org/10.1182/bloodadvances.2025016141

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy

Jibran Durrani, Leonard N. Chen, Ruba N. Shalhoub, Valentina Baez, Joshua Glass, Nu Ri Cha, Xiaoyang Ma, Zhijie Wu, Shouguo Gao, Jennifer Lotter, Olga Rios, Colin O. Wu, Willy A. Flegel, Neal S. Young, Emma M. Groarke, Bhavisha A. Patel

Blood Adv (2025) 9 (11): 2639–2650.

https://doi.org/10.1182/bloodadvances.2024015301

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation

Blood Adv (2025) 9 (10): 2570–2584.

https://doi.org/10.1182/bloodadvances.2024014177

Published: 2025

Journal Articles

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML

Blood Adv (2025) 9 (10): 2542–2552.

https://doi.org/10.1182/bloodadvances.2024014901

Published: 2025

Includes: Supplemental data

Journal Articles

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

Blood Adv (2025) 9 (10): 2553–2569.

https://doi.org/10.1182/bloodadvances.2024014879

Published: 2025

Includes: Supplemental data

Journal Articles

Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France

Blood Adv (2025) 9 (10): 2530–2541.

https://doi.org/10.1182/bloodadvances.2024015208

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma

Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies

A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations

A cure for the kiss of death?

On the road to improved therapies for therapy-related AML

Prebiotic fibre enteral supplementation post allogeneic transplantation; feasibility and impact on the microbiome

Impact of Concomitant Azoles on Ruxolitinib Treatment in Patients With GVHD: Post Hoc Analyses of REACH2 and REACH3

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA

Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR

Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only